Recent Updates
Recently added Catalysts

GammaCore

Phase 2

Chronic Cluster Headache | Unknown | Other |electroCore, Inc.|Last Updated: Apr 25, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment97
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01701245Prevention and Acute Treatment of Chronic Cluster Headache Compared to Standard of CarePHASE2 COMPLETED 97Oct 1, 2012Oct 1, 2014Apr 25, 201610 Belgium, Germany +2
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
A Change in the Frequency of Cluster Headache Attacks Per Week
4 weeks

The primary endpoint is the reduction in mean number of CH attacks per week. The number of CH attacks will be calculated as the sum of all attacks over the days in the run-in period and divided by the number of weeks, respectively for the last 14 days of treatment during the randomised phase. The reduction will then be the number of CH attacks during treatment period (last 14 days of the randomized treatment period) - number of CH attacks during run-in.

Secondary Endpoints
Pain Relief of Headache Attacks
baseline (2 weeks) and random period(last 2 weeks)
Adverse Events
10 weeks
EQ-5D-3L (EuroQoL 5 Questions and 3 Answering Levels) and a VAS (Visual Analogue Scale)
10 weeks (baseline 2 weeks, random 4 weeks and open label 4 weeks)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Standard of careNO_INTERVENTIONNo intervention, standard of care
GammaCoreACTIVE_COMPARATORThree stimulation treatments 2x/day 7 to 10 hours apart from one another. In addition, three stimulation treatments at the time of onset of symptoms of a headache attack.
Interventions
NameTypeDescription
GammaCoreDEVICEvagal stimulation
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 70 Years
SexALL
Healthy VolunteersNo
Study Sites10

Inclusion Criteria: 1\. Signed Informed Consent Form 2. Subjects between the age of 18-70, both genders 3. Subjects diagnosed with chronic cluster headache for at least 1 year, without remission periods or with remission periods lasting \<1 month, in accordance with the ICHD-II classification crite...

Countries:BelgiumGermanyItalyUnited Kingdom
Unlock Eligibility Criteria